Chronic hepatitis C virus management: 2000-2005 update (Q36348376)

13 August 2017

1 reference

title

Chronic hepatitis C virus management: 2000-2005 update (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

1 reference

Christine A Hughes

1

1 reference

PubMed ID

16368925

13 August 2017

Stephen D Shafran

series ordinal

2

1 reference

PubMed ID

16368925

13 August 2017

language of work or name

English

0 references

publication date

20 December 2005

1 reference

Annals of Pharmacotherapy

13 August 2017

1 reference

13 August 2017

40

1 reference

13 August 2017

74-82

1 reference

13 August 2017

1

1 reference

The epidemiology of hepatitis C virus infection

13 August 2017

1 reference

Approach to the patient with chronic hepatitis C virus infection

21 January 2018

1 reference

National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002

21 January 2018

1 reference

The management of chronic viral hepatitis: a Canadian consensus conference 2004.

21 January 2018

1 reference

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

Pegylated interferons for the treatment of chronic hepatitis C infection

21 January 2018

1 reference

Combined antiviral options for the treatment of chronic hepatitis C.

21 January 2018

1 reference

Pharmacokinetics of peginterferons

21 January 2018

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

21 January 2018

1 reference

Chronic Hepatitis C Virus Infection

21 January 2018

1 reference

Clinical trial results of peginterferons in combination with ribavirin

21 January 2018

1 reference

Management of hepatitis C virus genotype 4.

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

21 January 2018

1 reference

Adherence to combination therapy: influence on sustained virologic response and economic impact

21 January 2018

1 reference

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.

21 January 2018

1 reference

Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.

21 January 2018

1 reference

Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.

21 January 2018

1 reference

Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.

21 January 2018

1 reference

African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians

21 January 2018

1 reference

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

Side effects of therapy for chronic hepatitis C.

21 January 2018

1 reference

The management of side-effects during therapy for hepatitis C.

21 January 2018

1 reference

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

21 January 2018

1 reference

Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression.

21 January 2018

1 reference

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatotoxicity associated with the new antidepressants

21 January 2018

1 reference

Bupropion for treatment of interferon-induced depression

21 January 2018

1 reference

Anemia in the Treatment of Hepatitis C Virus Infection

21 January 2018

1 reference

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G263

1 reference

13 August 2017

1 reference

PubMed ID

16368925